VX-166

• Description :

  VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver[1].

• UNSPSC :

  12352005

• Target :

  Caspase

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/vx-166.html

• Smiles :

  FC(C(F)=CC(F)=C1F)=C1OCC([C@H](CC(O)=O)NC([C@@H](N2C(C(NC(OC)=O)=CC=C2)=O)CC)=O)=O

• Molecular Formula :

  C22H21F4N3O8

• Molecular Weight :

  531.41

• References & Citations :

  [1]John Pollard, et al. Treatment of liver diseases with a caspase inhibitor. Patent WO2010120880A1.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [800408-39-3]